<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571648</url>
  </required_header>
  <id_info>
    <org_study_id>AZA-MDS-005</org_study_id>
    <nct_id>NCT01571648</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability of oral azacitidine in the
      treatment of patients with Myelodysplastic Syndromes (MDS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK- Maximum concentration in plasma (Cmax)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK- Maximum concentration in plasma (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK- Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK- Time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Elimination rate constant (Kel)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK-Elimination rate constant (Kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Terminal half-life (T1/2,z)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK-Terminal half-life (T1/2,z)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK-Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Apparent total body clearance (CL/F)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK-Apparent total body clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Apparent volume of distribution (Vz/f)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 hours post-dose</time_frame>
    <description>PK-Apparent volume of distribution (Vz/f)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (type, frequency, severity, number of participants with adverse events)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Safety (type, frequency, severity, number of participants with adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Hematologic response and hematologic improvement)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Efficacy (Hematologic response and hematologic improvement)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Oral azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral azacitidine</intervention_name>
    <description>Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.</description>
    <arm_group_label>Oral azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must satisfy the following criteria to be enrolled in the study:

          -  Have a documented diagnosis of myelodysplastic syndromes (MDS) according to World
             Health Organization (WHO) 2008 classification

          -  Age â‰¥ 20 years;

          -  Written informed consent;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          -  Resolution of any toxic effects of prior anti-cancer therapy; and

          -  Negative urine or serum pregnancy test on females of childbearing potential.

        Exclusion Criteria:

        The presence of any of the following will exclude a patient from enrollment:

          -  Treatment with chemotherapy, radiotherapy, or surgery within 4 weeks of study
             registration;

          -  Pregnant or breast-feeding females;

          -  Previous or concomitant malignancy other than MDS;

          -  Significant active cardiac disease within the previous 6 months;

          -  Uncontrolled systemic infection or

          -  Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masamitsu Harata</last_name>
    <role>Study Director</role>
    <affiliation>Celgene K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celgene Trial Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Trial Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Trial Site</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Trial Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Trial Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

